Nurses Programme

Session 1 Natasha Nunan
10h50 Opening of nurses session – Welcome Natasha Nunan
10h50 to 11h20 Local perspective on apheresis Dr Yona Skosana (SANBS)
11h20 to 11h50 Correlation Between Disconnection During Stem Cell/Lymphocyte Apheresis and Microbial Findings in the Cell Product: A Single-Centre Retrospective Study with Ongoing Prospective Analyses Sr Senait Kahsai
DKMS (Germany)
11h50 to 12h20 Management of patient undergoing apheresis (pbsc collection) – nursing perspective Sr Bridget Mofokeng (SANBS)
12h20 to 12h55 Q & A  
13h00 to 14h00 Lunch
Session 2 Drina Heyns
14h00  to 14h30 Central Line Care and Infection Prevention in HSCT: Small Actions, Big Outcomes Natasha Nunan
14h30 to 15h00 Organ Toxicities in Oncology Sr Andrea Brummer
15h00 to 15h20 The First 100 Days: Nursing Surveillance After Allogeneic Stem Cell Transplant Sr Shamimah Diedericks
15h20 to 15h30 Q& A  
15h30 to 16h00 Refreshment break
Session 3 Shamimah Diedericks
16h00 to 16h30 CAR T therapy and CRS?
Case study on the first patient who received CAR T therapy on the African continent.		 Drina Heyns
(ACT Pretoria)
16h30  to 16h45 Oncology Buddies Karen Joseph and Laurelle Williams
16h45 to 17h20 A overview into Breast Cancer “The disease and Treatment” Antje Viljoen
Pharmacist
17h20 to 17h30 Q & A  
  Close  

Aspen Pharmacare, the number one pharmaceutical company in South Africa is your trusted partner in healthcare.

Aspen is a global specialty and branded pharmaceutical company with more than 170 years of heritage. Our medicines reach more than 115 countries worldwide, creating access to quality healthcare for people globally.

Aspen has 24 manufacturing facilities and holds international approvals from some of the most stringent global regulatory agencies. Our manufacturing capabilities enable us to serve a broad range of therapeutic areas through multiple dosage forms, including steriles, oral doses, liquids, semi-solids, biologicals, and APIs.

Aligned with our ethos “Healthcare. We Care.”, our basket reflects a combination of legacy, innovation and reliability, positioning Aspen as a preferred and trusted partner in advancing healthcare.

Aspen’s Strategic Partnerships and growth are guided by sustainable pillars. Collaborations with global pharmaceutical companies enhance Aspen’s product portfolio and expand market reach internationally.

Aspen’s greatest strength lies in our diverse and talented teams united by our shared purpose: to improve the health and quality of life of patients around the world.

We are dedicated to enhancing patient health and quality of life while fostering trust, creating shared value and making a meaningful impact as a responsible corporation.

Aspen Pharmacare, the number one pharmaceutical company in South Africa and the largest in Africa, is your trusted partner in healthcare.

https://www.aspenpharmasa.co.za

Reference 1: Based on internal analysis by Pharmacare Ltd t/a Aspen Pharmacare using data from the following source:
IQVIA South Africa Local TPM MAT FEBRUARY 2026. Brands measured in Rand value, reflecting estimates of real-world
activity. Copyright IQVIA.

Advancing Global Health Through Innovation and Impact in sub-Saharan Africa

MSD, known as Merck in the United States and Canada, leverages leading-edge science to save and improve lives globally. With over 130 years of innovation and more than 50 years in Africa, MSD expands access to medicines and vaccines while strengthening healthcare systems through partnerships, improving health outcomes across sub-Saharan Africa.

www.msdconnect.co.za/melanoma-info

AstraZeneca is a science-led, patient-focused biopharmaceutical company committed to transforming healthcare and improving outcomes for people around the world. As the burden of disease grows and populations age, we believe science, powered by digital, data and AI, is key to addressing the world’s most pressing healthcare challenges.

We strive to improve access to life-changing medicines and pioneering solutions, while also supporting earlier detection, integrated care pathways, and stronger health systems so more people can receive the right care at the right time. Powered by scientific innovation, and increasingly enabled by digital, data and AI, we are helping redefine cancer care, improve outcomes in chronic diseases, and expand access to care in a sustainable and responsible way.

Our approach is grounded in collaboration, inclusion, ethics, and sustainability, enabling us to work with partners across the healthcare ecosystem to bring forward new ideas and meaningful progress. Through science and partnership, AstraZeneca is helping shape a healthier future for patients, society, and the planet.

https://www.astrazeneca.com/country-sites/african-cluster.html

Activity ID: ZA-6886; Expiry date: 30 June 2028

Adcock Ingram is a Proudly South African company. Adcock Ingram manufactures, markets, sells and distributes a wide range of products. The diversified portfolio includes an extensive portfolio of branded and generic prescription medicines.

www.adcock.com

Acino is a Swiss pharmaceutical company headquartered in Zurich with a clear focus on selected markets in the Middle East, Africa, Ukraine and Eurasian countries, and Latin America.

We deliver quality pharmaceuticals to promote affordable healthcare in these emerging markets and leverage our high-quality pharmaceutical manufacturing capabilities and network to supply leading companies through contract manufacturing and out-licensing.

https://acino.swiss/

M-ZA-00002893 Expiration Date 07/03/2027

Roche Pharmaceuticals: Leading the Charge in Oncology

Roche is one of the world’s largest biotechnology company and has spent over 125 years redefining cancer care through a fusion of innovative therapies and precision medicine1.In Africa, Roche is one of the primary drivers of oncology advancements, leveraging a vast clinical trial network to deliver targeted treatments for HER2-positive breast cancer and now incorporating the lung cancer2.


Central to its regional mission is the Africa Breast Cancer Ambition, a bold initiative to rewrite the continent's survival narrative. Currently, only 5 in 10 African women survive breast cancer; Roche aims to increase this to 8 in 103 by 20404. To achieve this, Roche is committed to three critical pillars:

  • Early Detection: Increasing stage I/II diagnoses from 30% to 60%.5
  • Faster Diagnosis: Reducing the journey from symptoms to treatment to just 60 days.6
  • Treatment Access: Ensuring 80% of patients receive the standard of care.7

Through these interventions, Roche is dedicated to doing now what patients need next, pioneering an innovative pipeline to improve clinical outcomes and extend the lives of patients in South Africa.

https://www.roche.co.za/about


Roche Products (Pty) Ltd, P O Box 1469, Halfway House, 1685. Tel. +27-11-504-4746 Registration No. 1947/027044/07 Building E, Hertford Office Park, 90 Bekker Road, Vorna Valley, Midrand, 1686 Directors: R. Ferraro (Chairman) (Swiss) Dr S.D. Diale T.G. (South Africa) Renwick (British)

1 Roche South Africa. About Roche [Internet; updated 2026 Feb; cited 2026 Mar 2]. Available from: About Roche ZA

2 Roche. A new era of healthcare in Africa with AMA [Internet; updated 2026 Feb; cited 2026 Mar 2]. Available from: A new era of healthcare in Africa with AMA

3 Roche. African Breast Cancer Ambition (ABCA) [Internet; cited 2026 Mar 2]. Available from: Africa Breast Cancer Ambition

4 Africa Breast Cancer Council. Our Objectives [Internet; updated 2026; cited 2026 Mar 2]. Available from: Africa Breast Cancer Council Objectives

5 Africa Breast Cancer Council. Our Objectives [Internet; updated 2026; cited 2026 Mar 2]. Available from: Africa Breast Cancer Council Objectives

6 Africa Breast Cancer Council. Our Objectives [Internet; updated 2026; cited 2026 Mar 2]. Available from: Africa Breast Cancer Council Objectives

7 Roche Africa. Working together to help more women in Africa survive breast cancer [Internet; updated 2026 Feb; cited 2026 Mar 2]. Available from: Working together to help more women in Africa survive breast cancer